Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.
about
Angiotensin receptor blockers for heart failureDifferential clinical profile of candesartan compared to other angiotensin receptor blockersBinding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activationEfficacy of olmesartan amlodipine in Colombian hypertensive patients (soat study)Management of Hypertension Using Olmesartan Alone or in CombinationBlood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertensionAntihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.Cardiovascular effects of losartan and its relevant clinical application.Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.Pharmacokinetic evaluation of losartan.Olmesartan/amlodipine: a review of its use in the management of hypertension.End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations.Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.Comparative effectiveness analysis of amlodipine/renin-angiotensin system blocker combinations.Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
P2860
Q24199125-5FC52B4B-977D-471C-BAAE-519493E341D3Q24613321-EBEE6800-91E8-4AA4-BE3E-0D51DDB8EFD5Q28565562-7007238E-7E88-4EC2-AB4A-656F0D3E852CQ33604498-AFD6E2C2-B425-4211-9D1D-85A4BDC1EC0FQ33734043-1499D366-5D76-470A-8397-CEAD72011D3BQ34066477-2DA0946B-80D5-4561-BD01-7EE9DC1E4A31Q34118875-0904C65C-6290-4E63-A781-29B9A7F6C2CDQ34392647-869D185E-4A33-4C2E-96EF-2D9420D5A80FQ34614447-8BD6F124-7EEF-464B-A632-0CBE4AB56F6EQ35947641-08AC4629-832F-4B88-9FF8-4B53501F03B7Q37427232-F424B1D4-1D54-453D-B555-95DC49303517Q37427235-4A130F16-507F-431C-AC2A-7F1D77E9D320Q37595599-6D1919F4-A143-414F-B189-5CD304CAE231Q37761376-15D9A093-D1B7-41ED-9B88-CCFDC049233CQ37854746-DC3F3270-A6BC-42E3-831C-714D751D1C0DQ37864949-A99495F8-B655-4B64-A05E-9CB08DB61CDCQ37888664-A1B12339-8EDA-4508-B0EC-423545E7779AQ37973403-AD6F0CA4-0472-467A-9D9A-DEBC9303D811Q38079623-28BF3361-2F37-470D-9B7E-9CD86C824DC4Q42705972-F05D75BD-8E60-45E7-841F-13DD0B1DB577Q44967702-9821B720-344D-4D87-B186-B768F2CEDACCQ46296803-C6375AD2-4F76-4A32-AEDC-3B75A91E2B96Q48020817-0BFAADDF-7027-4A9B-92C7-9E77B5A2CB90Q53404727-0B609D5F-6C77-439D-B349-0B5FCBAEE04B
P2860
Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of angiotensin II t ...... ent of essential hypertension.
@en
Comparison of angiotensin II t ...... ent of essential hypertension.
@nl
type
label
Comparison of angiotensin II t ...... ent of essential hypertension.
@en
Comparison of angiotensin II t ...... ent of essential hypertension.
@nl
prefLabel
Comparison of angiotensin II t ...... ent of essential hypertension.
@en
Comparison of angiotensin II t ...... ent of essential hypertension.
@nl
P1433
P1476
Comparison of angiotensin II t ...... ent of essential hypertension.
@en
P2093
David H G Smith
P2860
P304
P356
10.2165/00003495-200868090-00003
P577
2008-01-01T00:00:00Z
P5875
P6179
1019777952